PNPLA3 and metabolic dysfunction-associated steatotic liver disease: The authors claim that MetS might mask the effects of hepatic copper and PNPLA3 [54]. Accordingly, Van Campenhout et al. have shown that even if copper concentration is lower in the early phase of NAFLD disease they were not able to highlight any differences in the progression of the disease [57].